Burden of noncommunicable diseases and COVID-19 pandemic prevention and control strategies
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20242581Keywords:
Noncommunicable diseases, COVID-19 pandemic, Prevention and control, Strategies, Political approach, BurdenAbstract
Noncommunicable diseases (NCDs) are the leading cause of death in 21st century. The risk factors for development and progression of NCDs include sedentary lifestyle, inadequate fruits and vegetables intake, tobacco use, high blood pressure, high total cholesterol levels, obesity, high salt intake, low physical activity, and air pollution. People with NCDs and comorbidities like hypertension, cardiovascular diseases, diabetes, chronic respiratory infection and cancer are more vulnerable to severe COVID-19 infection that ultimately results into mortality. To reduce the impact of NCDs on COVID-19 cases, prevention is the best measure. Primary and secondary level prevention of NCDs plays a main role to control bad outcome in COVID-19 cases. The strategies that are required to address this comorbidity includes integration and convergence of the existing communicable and NCD programs, strengthening health care systems by giving major focus on primary health care services, health and wellness centers, universal health coverage, updating guidelines, enhancing community participation, capacity building, appropriate policy making, multi-sectoral participation and coordination.
References
World Health Organization. Noncommunicable Diseases. 2018. Available at: https://www.who.int.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus–infected pneumonia. New Engl J Med. 2020;382:1199-207.
Lauer SA, Grantz KH, Bi Q. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020;172:577-82.
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72. cases from the Chinese center for disease control and prevention. JAMA 2020;26:48.
Chow N, Fleming-Dutra K, Gierke R, Hall A, Hughes M, Pilishvili T, et al. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States. Morbidity and Mortality Weekly Report. 2020;28:69.
Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475-81.
Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int J Infect Dis 2020;94:91-5.
The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. China CDC Weekly. 2020;2:113-22.
Centers for disease control and prevention. groups at higher risk for severe illness. 2020. Available at: https://www.cdc.gov.
Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999;26:259-65.
García-Valero J, Olloquequi J, Montes JF. Deficient pulmonary IFN-β expression in COPD patients. PLoS One 2019;14:217803.
AlGhatrif M, Cingolani O, Lakatta EG. The dilemma of coronavirus disease 2019, aging, and cardiovascular disease: insights from cardiovascular aging science. JAMA Cardiol 2020;13:29.
Wrapp D, Wang N, Corbett KS. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;25:07.
Kunal S, Gupta K, Sharma SM, Pathak V, Mittal S, Tarke C. Cardiovascular system and COVID-19: perspectives from a developing country. Monaldi Arch Chest Dis. 2020;90:1305;231-41.
António Guterres. The Recovery from the COVID-19 crisis must lead to a different economy. 2020. Available at: https://www.un.org/en/un-coronavirus.
